Annabel Kartal-Allen is a reporter for Clinical Trials Arena, Pharmaceutical Technology and Medical Device Network based in London, UK. Annabel holds interests in oncology, neurology and metabolic diseases. She has previous experience reporting for both the pharmaceutical and nutraceutical industries, and holds a BSc in Biology from the University of Sussex. Contact Annabel
As the pharmacological treatment landscape continues to evolve, biologics are becoming increasingly incorporated into therapeutic regimens across a broad range…
Johnson & Johnson’s (J&J’s) blockbuster cancer therapy, Darzalex (daratumumab), is set to secure a wider recommendation from the UK’s health…
Incyte has outlaid up to $2bn to acquire Star Therapeutics-owned subsidiary, Vega Therapeutics – adding a late-stage candidate to its…
As the 2026 American Diabetes Association (ADA) conference draws to a close for another year, Pharmaceutical Technology gives you a…
Parabilis Medicines is hoping to raise $475m in an initial public offering (IPO) as it set its sights on the…
While the 2026 American Society of Clinical Oncology (ASCO) conference may be over for another year, the editorial team at…
Eli Lilly has penned a research collaboration deal with Massachusetts-based biotech, Ascidian Therapeutics, to discover and develop drugs for kidney…
Two bipartisan Michigan lawmakers have joined forces to debut new legislation that, if enacted, could significantly suppress dealmaking between Chinese…
Contraline has closed a $92.5m Series B financing round to take its topical male contraceptive to late-stage trials – potentially…
With the 2026 American Society of Clinical Oncology (ASCO) conference wrapping up, many are turning their attention to key readouts…
